- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Sharon Phares Lists the Many Factors Physicians Should Consider When Choosing Therapies
Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, explained the importance of taking multiple factors into consideration when making health care decisions.
Sharon Phares, PhD, MPH, chief scientific officer of the National Pharmaceutical Council, explained the importance of taking other factors in addition to gender into consideration when making health care decisions, marking Women's Health Month.
Transcript
How well do health technology assessments currently take into account gender differences? How can it be done better?
Currently, gender differences are not looked at very often only when they are specific to a therapy. So, for instance, if you're looking at a therapy for breast cancer, although men can get breast cancer, they're less likely to. But how they could do it differently is to really look at differences by groups. Do women get impacted the same as men and is the value the same? Similarly, it can be said for other groups, not just men and women, but also people of color, people of different ethnicities, etc, to kind of look at those combinations of gender and racial or cultural identity, as well as some issues around things like socioeconomic status, which can impact the value, so to speak, of a medication for a certain group.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
